» Articles » PMID: 34855984

Novel Agonist and Antagonist Radioligands for the GLP-2 Receptor. Useful Tools for Studies of Basic GLP-2 Receptor Pharmacology

Abstract

Background: Glucagon-like peptide-2 (GLP-2) is a pro-glucagon-derived hormone secreted from intestinal enteroendocrine L cells with actions on gut and bones. GLP-2(1-33) is cleaved by DPP-4, forming GLP-2(3-33), having low intrinsic activity and competitive antagonism properties at GLP-2 receptors. We created radioligands based on these two molecules.

Experimental Approach: The methionine in position 10 of GLP-2(1-33) and GLP-2(3-33) was substituted with tyrosine (M10Y) enabling oxidative iodination, creating [ I]-hGLP-2(1-33,M10Y) and [ I]-hGLP-2(3-33,M10Y). Both were characterized by competition binding, on-and-off-rate determination and receptor activation. Receptor expression was determined by target-tissue autoradiography and immunohistochemistry.

Key Results: Both M10Y-substituted peptides induced cAMP production via the GLP-2 receptor comparable to the wildtype peptides. GLP-2(3-33,M10Y) maintained the antagonistic properties of GLP-2(3-33). However, hGLP-2(1-33,M10Y) had lower arrestin recruitment than hGLP-2(1-33). High affinities for the hGLP-2 receptor were observed using [ I]-hGLP-2(1-33,M10Y) and [ I]-hGLP-2(3-33,M10Y) with K values of 59.3 and 40.6 nM. The latter (with antagonistic properties) had higher B and faster on and off rates compared to the former (full agonist). Both bound the hGLP-1 receptor with low affinity (K of 130 and 330 nM, respectively). Autoradiography in wildtype mice revealed strong labelling of subepithelial myofibroblasts, confirmed by immunohistochemistry using a GLP-2 receptor specific antibody that in turn was confirmed in GLP-2 receptor knock-out mice.

Conclusion And Implications: Two new radioligands with different binding kinetics, one a full agonist and the other a weak partial agonist with antagonistic properties were developed and subepithelial myofibroblasts identified as a major site for GLP-2 receptor expression.

Citing Articles

Lipid regulation of the glucagon receptor family.

Oqua A, Manchanda Y, McGlone E, Jones B, Rouse S, Tomas A J Endocrinol. 2024; 261(3).

PMID: 38614123 PMC: 11103681. DOI: 10.1530/JOE-23-0335.


New Insights into the Structure and Function of Class B1 GPCRs.

Cary B, Zhang X, Cao J, Johnson R, Piper S, Gerrard E Endocr Rev. 2022; 44(3):492-517.

PMID: 36546772 PMC: 10166269. DOI: 10.1210/endrev/bnac033.


N-terminal alterations turn the gut hormone GLP-2 into an antagonist with gradual loss of GLP-2 receptor selectivity towards more GLP-1 receptor interaction.

Gabe M, Gasbjerg L, Gadgaard S, Lindquist P, Holst J, Rosenkilde M Br J Pharmacol. 2022; 179(18):4473-4485.

PMID: 35523760 PMC: 9541843. DOI: 10.1111/bph.15866.


Novel agonist and antagonist radioligands for the GLP-2 receptor. Useful tools for studies of basic GLP-2 receptor pharmacology.

Gadgaard S, van der Velden W, Schiellerup S, Hunt J, Gabe M, Windelov J Br J Pharmacol. 2021; 179(9):1998-2015.

PMID: 34855984 PMC: 9303331. DOI: 10.1111/bph.15766.

References
1.
Richards P, Parker H, Adriaenssens A, Hodgson J, Cork S, Trapp S . Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model. Diabetes. 2013; 63(4):1224-33. PMC: 4092212. DOI: 10.2337/db13-1440. View

2.
Gasbjerg L, Christensen M, Hartmann B, Lanng A, Sparre-Ulrich A, Gabe M . GIP(3-30)NH is an efficacious GIP receptor antagonist in humans: a randomised, double-blinded, placebo-controlled, crossover study. Diabetologia. 2017; 61(2):413-423. DOI: 10.1007/s00125-017-4447-4. View

3.
Baker J, Hill S . Multiple GPCR conformations and signalling pathways: implications for antagonist affinity estimates. Trends Pharmacol Sci. 2007; 28(8):374-81. PMC: 2169386. DOI: 10.1016/j.tips.2007.06.011. View

4.
Askov-Hansen C, Jeppesen P, Lund P, Hartmann B, Holst J, Henriksen D . Effect of glucagon-like peptide-2 exposure on bone resorption: Effectiveness of high concentration versus prolonged exposure. Regul Pept. 2012; 181:4-8. DOI: 10.1016/j.regpep.2012.11.002. View

5.
Schiellerup S, Skov-Jeppesen K, Windelov J, Svane M, Holst J, Hartmann B . Gut Hormones and Their Effect on Bone Metabolism. Potential Drug Therapies in Future Osteoporosis Treatment. Front Endocrinol (Lausanne). 2019; 10:75. PMC: 6399108. DOI: 10.3389/fendo.2019.00075. View